Dungiven
On your point 3 if an generic is made that matches the Bene DMF chemical signature on file with the FDA, are you saying the new generic would have to undergo new trails even if the generic competitor matches the Bene chemical signature on file. What rules are these?
Paradigm patent rejection, page-44
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.035(12.7%) |
Mkt cap ! $108.4M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 31.0¢ | 27.5¢ | $108.9K | 371.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 17420 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |